A year after acquiring Phenex’s farnesoid X receptor (FXR) agonist to boost its non-alcoholic steatohepatitis (NASH) portfolio, Gilead Sciences has struck another deal to acquire Nimbus Apollo for its acetyl-CoA carboxylase (ACC) inhibitor programme and lead asset, NDI-010976, which is ready to enter Phase II clinical trials for the treatment of NASH. With the addition of new mechanism of action to the pool, the acquisition will bolster Gilead’s already existing mid-stage NASH pipeline.